Mark Stejbach insider trades
Open-market stock purchases and sales by Mark Stejbach, Director at Indivior Pharmaceuticals, Inc, from SEC Form 4 filings since Apr 9, 2010.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +66%.